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We have created early-onset transgenic (Tg) models by
exploiting the synergistic effects of familial Alzheimer’s
disease mutations on amyloid b-peptide (Ab) biogenesis.
TgCRND8 mice encode a double mutant form of amyloid
precursor protein 695 (KM670/671NL1V717F) under the
control of the PrP gene promoter. Thioflavine S-positive
Ab amyloid deposits are present at 3 months, with
dense-cored plaques and neuritic pathology evident
from 5 months of age. TgCRND8 mice exhibit 3,200–
4,600 pmol of Ab42 per g brain at age 6 months, with an
excess of Ab42 over Ab40. High level production of the
pathogenic Ab42 form of Ab peptide was associated with
an early impairment in TgCRND8 mice in acquisition
and learning reversal in the reference memory version
of the Morris water maze, present by 3 months of age.
Notably, learning impairment in young mice was offset
by immunization against Ab42 (Janus, C., Pearson, J.,
McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D.,
Chishti, M. A., Horne, P., Heslin, D., French, J., Mount,
H. T. J., Nixon, R. A., Mercken, M., Bergeron, C., Fraser,
P. E., St. George-Hyslop, P., and Westaway, D. (2000)
Nature 408, 979–982). Amyloid deposition in TgCRND8
mice was enhanced by the expression of presenilin 1
transgenes including familial Alzheimer’s disease muta-
tions; for mice also expressing a M146L1L286V preseni-
lin 1 transgene, amyloid deposits were apparent by 1
month of age. The Tg mice described here suggest a
potential to investigate aspects of Alzheimer’s disease
pathogenesis, prophylaxis, and therapy within short
time frames.
Alzheimer’s disease, the most common cause of dementia,
has a complex etiology involving both genetic and environmen-
tal determinants. It is characterized by cerebral amyloid de-
posits formed from the amyloid b-peptide (Ab),1 neuronal loss,
and intracellular deposits denoted neurofibrillary tangles
(NFTs), aggregations of hyper-phosphorylated forms of the mi-
crotubule-associated protein tau (t). Genetic analyses of di-
verse familial Alzheimer’s disease (FAD) kindreds indicate bio-
synthesis of the amyloid b-peptide (Ab), generated by
secretase-mediated endoproteolysis of the amyloid precursor
protein (APP), is a common denominator in inherited forms of
the disease. In the case of chromosome 21-linked FAD kin-
dreds, mutations in APP are found in close proximity to the
endoprotease sites where Ab is excised by the action of b- and
g-secretases (2–6). Mutations in presenilins 1 and 2 are
thought to enhance cleavage of APP at the g-secretase site
(7–9). Finally, the e4 allele of the ApoE gene, which is corre-
lated with increased susceptibility to late-onset AD (10), is
found to enhance the formation of mature plaques in certain
APP transgenic mice (11). These genetic data indicate elevated
Ab biogenesis or accumulation is likely a crucial pathogenic
event in all forms of AD (i.e. both familial and sporadic AD).
This conclusion finds a parallel in studies indicating that Ab is
neurotoxic (12–14).
Since there are no naturally occurring rodent forms of AD,
there has been great interest in creating accurate transgenic
facsimiles of this disease. Such disease models have the poten-
tial to stratify pathogenic events and practical utility for test-
ing interventions directed against synthesis or deposition of the
Ab peptide. However, despite intense effort, remarkably few
models exist (reviewed in Ref. 15). Some models fail to produce
APP and/or its metabolites by physiologically appropriate path-
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ways, and in cases where this caveat does not apply, the trans-
genic animals may display only facets of the AD phenotype
(16). With regard to neuropathology, the phenotypes created
thus far include amyloid deposits that closely resemble those
seen in AD, selective neuronal loss (in one instance), some
hyperphosphorylation of tau, but no deposition of NFTs (17–
20). Neuropathological abnormalities in singly transgenic mice
may not appear until 6–9 months of age and may not be robust
until animals are well in excess of 1 year of age (see “Discus-
sion”). Other complications encountered in these models in-
clude hippocampal atrophy (21), neonatal lethality attributed
to overexpression of APP (22, 23), and complex and variable
relationships between cognitive dysfunction and transgene ex-
pression (18, 21, 23–25). Here we describe a new line of trans-
genic mice that exhibits deposition of Ab-amyloid and robust
cognitive deficits by the age of 3 months. These mice have a
demonstrated utility for assessing procedures that interfere
with amyloidogenesis (1) and may serve as a platform to create
more sophisticated models of AD.
MATERIALS AND METHODS
Construction and Analysis of Tg Mice—The APP695 cDNA cassette
was based upon an isolate of the cDNA clone described by Kang et al.
(26). A SmaI to SpeI fragment including 90 and 269 base pairs of the wt
APP cDNA 59- and 39-untranslated region was cloned into the plasmid
vector pUC19 (27). This clone was subjected to mutagenesis using the
“transformer” protocol (CLONTECH) to convert the 59 SmaI site to a
SalI site, with a second SalI site deriving from the pUC19 polylinker.
The ;2.4-kilobase pair SalI fragment was excised and inserted into the
SalI site of pBR322 (28), to exclude extraneous polylinker sites and
thereby facilitate swapping of internal APP restriction fragments con-
taining either Swedish (KM670/671NL) or Swedish plus Indiana
(V717F) mutations (“Quick-change”, Stratagene Inc.). Completed plas-
mids were sequenced in their entirety with a total of 12 sequencing
primers covering the APP coding region, to exclude the possible pres-
ence of erroneous mutations either present in the starting plasmids or
introduced during in vitro manipulations. SalI fragments of APP or
XhoI fragments of PS1 (9) were then cloned into cos.Tet (29). NotI
transgene fragments excised from this cosmid vector were purified and
injected into oocytes of different genetic backgrounds as noted, and
founder animals were identified by dot-blot hybridization analysis of
genomic DNA using a probe within the hamster PrP gene 39-untrans-
lated region as described previously (9, 30). Double transgenic mice
deriving from crosses of transgene heterozygotes were identified by
dot-blot hybridization analysis using human APP or PS1 cDNA probe
fragments.
Protein Analysis—Western blots were performed by enhanced chemi-
luminescence as described previously (9), except ECL-Plus (Amersham
Pharmacia Biotech) was used in conjunction with a “Storm” imaging
system (Molecular Dynamics) for quantitative analyses. For ELISA
analysis, C3H/B6 3 FVB/N mice at 4, 6, 8, 10, and 26 weeks of age were
transcardially perfused with cold saline. The entire brain was removed
and snap-frozen until analysis. Cerebral Ab was solubilized in a 5 M
guanidine HCl, 50 mM Tris-HCl, pH 8.0 buffer (31), agitated, aliquoted,
and stored at 280 °C. Thawed aliquots were diluted 10-fold or more and
assessed for Ab40 or Ab42 using commercially available enzyme-linked
immunosorbent assays (ELISAs) specific for either Ab40 or Ab42 and
calibrated with synthetic Ab peptides (BIOSOURCE International).
The Ab40 ELISA does not display any cross-reactivity with Ab42 or
Ab43, and the Ab42 ELISA does not react with either Ab40 or Ab43.
Each brain was analyzed in duplicate or triplicate, with the average
value reported for each brain.
Survival Census—All pups were weaned at an age between 21 and 24
days. The identification of pups genotypes was carried out between 23
and 26 days of age. Therefore, the reliable estimation of Tg mice sur-
vival is limited to their post-weaning age. Statistical analysis of sur-
vival as a function of genetic background was carried out on three
cohorts of TgCRND8 mice as follows: (C57) 3 (C3H/C57), (FVB) 3
(C3H/C57), and (C3H/C57/129SvEv/Tac) 3 (129SvEv/Tac). For compar-
ative purposes the survival of non-Tg littermates was included, and the
analysis was performed for the 1st year of life. Since the mortality of
non-Tg mice was minimal (1 non-Tg mouse out of the total of 158
included in the analysis died at the age of 26 days), non-Tg mice were
pooled across their genetic backgrounds for graphical presentation and
statistical analyses. The probability of survival was assessed by the
Kaplan-Meier technique (32), computing the probability of survival at
every occurrence of death, thus making it particularly suitable for small
sample size cases with variable event intervals. The comparisons of
cumulative survival curves for each genetic background of mice were
performed using Tarone-Ware test, which weighs early events less than
log rank or Breslow tests.
Histology and Immunohistochemistry—Mice were anesthetized and
perfused with saline in accordance with The Canadian Council for
Animal Care guidelines. Generally, brains were removed and bisected
in the mid-sagittal plane. One-half was snap-frozen, and the portion for
immunohistochemistry was fixed in 10% neutral buffered formalin for a
minimum of 48 h. These specimens were then batch-processed on an
automatic tissue processor overnight with vacuum on each station to
aid penetration. Paraffin sections were cut at 5 microns and affixed to
Fisher brand Superfrost/Plus slides to ensure adhesion. Sections were
stained by Bielschowsky’s silver impregnation, cresyl violet, thioflavine
S, and Luxol Fast Blue combined with hematoxylin and eosin, as noted
in the figure legends. For general morphological characteristics, 12
TgCRND8 mice from the hybrid C3H/B6 background, age 43–440 days,
were studied. Additionally, 5 TgCRND8 mice (n 5 2, 213 days; n 5 3,
282 days) and 4 non-transgenic controls (n 5 3, 213 days; n 5 1, 282
days) were sectioned coronally to investigate hippocampal morphology.
The percent volume occupied by the dorsal hippocampus within the
surrounding brain regions was estimated using the Cavaleri point
counting method. Paraffin-embedded brains were serially sectioned on
a rotary microtome at a thickness of 10 mm (as described above) and
stained with either hematoxylin and eosin or cresyl violet to delineate
the hippocampal borders. The hippocampus was defined to include all
regions of the hippocampus proper, hilus, and dentate gyrus. To repre-
sent the dorsal hippocampal region a total of 6 serial sections were
collected for analysis (every 15th section, starting with the first section
in which the hippocampus was visible). Brain sections were visualized
using a video microscopy system (Zeiss Axoplan, using a lens for 3 4
magnification) and a superimposed point grid (680 mm spacing). Points
falling over the hemisphere and those falling over the hippocampus
were tallied. Volumes were then estimated using the formula: V 5
Spointszarea per pointzsection thicknesszsection spacing. Student t tests
were performed to compare mean volume data.
For immunohistochemistry, all sections were blocked in dilute (3%)
hydrogen peroxide and non-immune goat serum. Epitope retrieval, in
the form of a 5-min immersion in formic acid, was carried out prior to
demonstration of amyloid and synaptophysin immuoreactivity. In all
cases the primary antibody was left to react overnight at 4 °C. The
remaining steps using the Dako StreptABC complex-horseradish per-
oxidase-conjugated “Duet” anti-mouse/rabbit antibody kit were com-
pleted according to the protocols provided by the manufacturer. End
products were visualized with diaminobenzidine. Sections were lightly
counterstained with hematoxylin and were resin-mounted. The sources
of the antibodies used were as follows: 369 from Sam Gandy; 4G8 versus
Ab residues 17–24 from Richard Rubenstein; Ab42, 3542 from Fre´de´ric
Checler; 6F/3D versus Ab residues 8–17, synaptophysin, and anti-
ubiquitin from Dako Inc.; 6E10 versus Ab residues 1–16 from Senetek
Inc.; glial fibrillary acidic protein monoclonal from Roche Molecular
Biochemicals; NF200 from Novo Castra Laboratories; CD11b from
Chemicon Labs; and hyperphosphorylated tau, AT8, from Innogenetics,
Gent, Belgium. The 6F/3D antibody was of particular use for quantita-
tive studies using image analysis software as it visualized structures
(i.e. dense-cored plaques) with sharp boundaries.
Behavioral Tests and Data Analysis—Experimentally naive
TgCRND8 mice were tested at 11 weeks of age in two cohorts (NTg 5 10,
Nnon-Tg 5 7 in total) in the reference memory version of Morris water
maze test. The water maze apparatus, mouse handling, and general
testing procedure are described elsewhere (1, 33). Prior to the spatial
learning training, all mice underwent non-spatial pre-training (NSP),
to assess swimming abilities and familiarize mice with the test (1). Two
days following the NSP phase, all mice underwent a reference memory
training with a hidden platform placed in the center of one quadrant of
the pool (northeast) for 5 days, with 4 trials per day. After the last trial
of day 5, the platform was removed from the pool and each mouse
received one 60-s swim “probe trial.” Escape latency (in seconds), length
of swim path (centimeter) and swim speed (cm/s), were recorded using
an on-line HVS image video tracking system (33). For the probe trials,
an annulus crossing index was calculated, which represents the number
of passes over the platform site minus the mean of passes over alter-
native sites in other quadrants. The index expresses the spatial place
preference and controls for alternative search strategies without place
preferences, such as circular search (34, 35). Behavioral data was an-
alyzed using a mixed model of factorial analysis of variance. Degrees of
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freedom were adjusted by Greenhouse-Geisser epsilon correction for
heterogeneity of variance.
RESULTS
Creation of TgCRND8 Mice Expressing Mutant APP
Previous experiments have indicated that overexpression of
APP above a threshold of ;43 endogenous is a prerequisite for
deposition of amyloid plaques in the central nervous system
(18, 22). To avoid the toxic effects associated with these levels
of APP overexpression (22, 23, 36, 37), we exploited (i) permis-
sive strain backgrounds and (ii) APP cassettes, including mul-
tiple mutations, to maximize production of Ab for a given level
of APP expression. Transgene constructs were based upon a
cDNA cassette encoding the major APP isoform in human
brain, APP695. This cassette was modified to include either one
or two FAD mutations: the “Swedish” mutation (K670N,
M671L) and the “Indiana” mutation (V717F), lying adjacent to
the N- and C-terminal boundaries of the APP Ab domain,
respectively. APPSwe and APPSwe1717 cDNAs were intro-
duced into cos.Tet (29), a cosmid-based expression vector de-
rived from the Syrian hamster prion protein gene. This vector
directs position-independent transgene expression in central
nervous system neurons and, to a much lesser extent, astro-
cytes (38–41). Microinjections into C3H/HeJ 3 C57BL/6J or
(C3H/HeJ 3 C57BL/6J) 3 C57BL/6J oocytes (the strains are
hereafter referred to as C57 and C3H) yielded a number of
putative founders but just two stable transgenic lines desig-
nated Tg CRND6 and TgCRND8. These lines harbor APPSwe
and APPSwe1V717F transgenes, respectively.
Expression of APP and Ab Peptide in TgCRND8 Mice
APP-specific antibodies were used to establish transgene
expression from founder lines, with previously characterized
TgAPPwt6209 transgenic mice providing a point of reference
(22). Use of the N-terminal antibody 22C11, which reacts with
mouse and human APP, demonstrated overexpression of the
full-length mature form of APP of ;120 kDa and different
lower molecular mass species of 100 kDa (which are not re-
solved in this gel system), including immature APP, and APP
cleaved at the a- and b-secretase sites, APPSa and APPSb (Fig.
1A). Overexpression in the TgCRND8 line relative to mouse
APP holoprotein detected in non-Tg controls was estimated by
quantitative image analysis at ;5-fold. Similar results for high
molecular weight APP species were obtained with antibody
369, which reacts with an epitope close to the C terminus of
APP shared by mouse and human APP (Fig. 1A). Lower molec-
ular weight species deriving from APP processing were also
observed in brain extracts of TgCRND8 and TgCRND6 mice
analyzed with the human APP-specific monoclonal antibody
6E10 antiserum (epitope positioned N-terminal to the a-secre-
tase cleavage site) and antibody 369. These polypeptides rep-
resent APP C-terminal stubs arising from cleavage at the
a- and b-secretase sites, with antibody 369 recognizing both
species and antibody 6E10 recognizing only the longer b-stubs.
As anticipated, the APP6209 Tg line encoding wt human APP
does not exhibit b-stubs (as it lacks the Swedish mutation that
favors cleavage at this position) but exhibits a-stubs with a re-
duced electrophoretic mobility due to the inclusion of a c-Myc
epitope tag within the C terminus of the APP cDNA cassette (22).
In TgCRND8 mice, increasing levels of a 4-kDa species (but
not b-stubs) were detected by Western blot analysis as the
animals aged (Fig. 1B). To investigate the composition of these
4-kDa Ab peptide species, we performed ELISAs specific for
Ab40 and Ab42. Both human Ab40 and Ab42 were detected in
the brains of Tg CRND8 mice. No signals above background
were detected in non-Tg animals. Levels of both peptides in-
creased with age, although in different fashions (Table I). Thus
Ab40 levels were stable between 4 and 10 weeks of age. Ab42
increased slowly between 4 and 8 weeks, with a potent increase
at age 10 weeks, such that it predominated over Ab40 by a ratio
of ;5:1. There was considerable spread in Ab40 and Ab42
levels in 10-week-old mice, with levels of Ab40 varying from 25
to 234 ng/g of brain and Ab42 ranging from 115 to 728 ng/g of
brain. The increase in Ab42 and the sample-to-sample varia-
tion between mice at age 10 weeks likely represents a transi-
tion point as Ab42, first present in soluble form, begins to
assemble into insoluble amyloid deposits. Measured at 6
months of age, levels of both Ab42 and Ab40 were enormously
FIG. 1. Western blot analysis of transgene expression. 10% brain homogenates made in 0.32 M sucrose were diluted with Laemmli buffer,
sonicated, and run on 10–20% Tricine gradient gels (NOVEX). Following transfer to nitrocellulose, human APP and PS1 were detected using C-
and N-terminal-specific mAbs and developed by ECL (Amersham Pharmacia Biotech). A, comparison of APP expression levels in Tg lines. 1st lane,
Non-Tg; 2nd lane, Tg CRND6; 3rd lane, Tg CRND8; and 4th lane, Tg APP6209. Proteins were detected with human APP-specific C-terminal mAb
6E10 (left panel), C-terminal antibody 369 reactive against mouse and human APP (right panel), and N-terminal antibody 22C11, also reactive
against mouse and human APP (lower panel). Positions of high molecular weight APP holoprotein and holoprotein derivatives (“APP holoprotein”),
and C-terminal stubs are indicated. B, time course of Ab accumulation in Tg CRND8 mice: 1st lane, 60 days; 2nd lane, 120 days; 3rd lane, 180 days;
4th lane, 240 days; and 5th lane, 300 days. Detected with human-specific APP C-terminal mAb 6E10. C, comparison of protein expression levels
in Tg mice expressing single and double mutants of PS1. Normalized samples of brain homogenates are presented. Detection is with the
human-specific PS1 N-terminal mAb NT-1 (72). Lane 1, Non-Tg; lane 2, TgPS1(L286V)1274; lane 3, TgPS1(WT)1098; and lanes 4 and 5 represent
samples from TgPS1(L286V1M146L)6500 mice.
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increased and were ;510 and 190 times, respectively, the lev-
els observed in 4-week-old mice (which are free of amyloid
plaque deposits; Fig. 5A).
Postnatal Lethality in TgCRND8 Mice
To gain insight into the ability of genetic backgrounds to
modulate lethality associated with APP overexpression (and,
from a practical point of view, to preempt premature extinc-
tion), the newly established TgCRND8 line was bred to differ-
ent strain backgrounds. Progeny of an F1 cross to the C3H/HeJ
(“C3H”) strain were bred to mice derived from FVB/N and
129SvEv/Tac backgrounds. Estimated Kaplan-Meier cumula-
tive survival curves for TgCRND8 mice and their littermates
during post-natal development are presented in Fig. 2. Inspec-
tion of the curves clearly indicates improved survival of mice
with the APP transgene expressed on the (C57) 3 (C3H/C57)
genetic background. In this cohort of Tg mice (n 5 52), 20 mice
died before the age of 120 days, decreasing their survival to
60% and with three deaths at 130 days and three further
deaths after 250 days. When the APP transgene was expressed
on either (C3H/C57/129SvEv/Tac) 3 (129SvEv/Tac) or (FVB) 3
(C3H/C57) genetic backgrounds (n 5 12 and n 5 41 respective-
ly), survival dropped rapidly to 25–40% within the first 120
days of their post-natal life (Fig. 2). After this time point,
survival with the (C3H/C57/129SvEv/Tac) 3 (129SvEv/Tac) ge-
netic background dropped slightly to 33% (one death at 159
days) with only 25% (3 mice) of the cohort surviving until 365
days. Similarly, the survival of the TgCRND8 mice with
(FVB)3(C3H/C57) background dropped rapidly within the first
120 days of post-natal age (Fig. 2) with 17% of mice (n 5 7)
surviving until 365 days of age. The survival of mice with the
(C57) 3 (C3H/C57) was significantly better than survival of Tg
mice with (FVB) 3 (C3H/C57) or (C3H/C57/129SvEv/Tac) 3
(129SvEv/Tac) backgrounds (Tarone-Ware statistics: 5.13, p ,
0.05, and 19.01, p , 0.001, respectively). The survival curves of
the latter two genetic backgrounds did not differ significantly
from each other (Tarone-Ware statistics: 0.42, p . 0.05), and
the survival of TgCRND8 mice with the three genetic back-
grounds was significantly different from the survival of non-Tg
littermates (Tarone-Ware statistics .50, all p values , 0.001.
Although these data suggest significantly increased mortal-
ity of TgCRND8 mice as a consequence of a genetic contribution
of 129SvEv/Tac or FVB mouse strains, some caveats have to be
taken into consideration. First, the relatively small sample
sizes of the studied cohorts, especially with the 129SvEv/Tac
strain, where only a few mice survived for a long period, may
not reliably reflect survival rates at later stages of life. The
comparisons of larger cohorts should provide better estimation
of survival curves. Second, future survival censuses must be
extended to the pre-weaning developmental stage. The selec-
tive survival of pups before weaning, or for that matter at the
pre-natal stage of development, may cause a bias of a particu-
lar cohort entering post-weaning stage. Also, the genetic com-
position of the particular outbred TgCRND8 parent might be a
greater contributor to the differences in survival among the
crosses than the composition of the inbred parent. Nonetheless,
the major finding of the survival analysis, that the (C57) 3
(C3H/C57) genetic background significantly reduces mortality
in TgCRND8 mice, is in accord with our starting hypothesis.
Fifty percent of the studied cohort of 52 mice survived for a year
with minimal mortality observed after the first 3 months of
age. As shown in previous investigations, the cause of post-
natal lethality was not obvious (22). No overt changes were
revealed by routine histopathology, although it should be noted
that seizures were observed in a small fraction of TgCRND8
animals, and APP transgenes have been correlated with al-
tered vascular responses (37).
Cognitive Changes in TgCRND8 Mice
Non-spatial Pre-training—Partial results related to the im-
paired acquisition of spatial information, as measured by the
escape latency, were reported previously for a small cohort of
mice (1). Here we present a characterization of a larger cohort
of mice, and we include their behavioral analysis during NSP.
The analysis showed that during NSP at age 10.5 weeks
TgCRND8 mice performed comparably to non-Tg littermates
when randomly searching the pool for a hidden platform. Es-
cape latencies and lengths of search paths in the last trial of
TABLE I
Ab peptide species in young TgCRND8 mice
Age Gendera
Ab42b Ab40b Ab42/Ab40
Mean 6 S.D. Range Mean 6 S.D. Range Mean 6 S.D.
weeks
4 3F, 3M 40.9 6 4.1 35–46 55.2 6 3.6 49–60 0.74 6 0.04
6 4F, 3M 55.3 6 6.9 47–63 61.3 6 11.4 48–82 0.93 6 0.19
8 4F, 3M 96.9 6 56.3 59–215 55.8 6 4.8 46–63 1.07 6 0.83
10 9F, 1M 298.1 6 209.9 115–728 69.5 6 61.1 25–234 5.06 6 1.56
26 5M 20,783 6 6599 12,476–29,260 10,584 6 1495 9,262–13,157 1.96 6 0.59
a Using unpaired t tests, the levels of Ab40 and Ab42 were not found to differ between males and females, from 4 to 8 weeks of age.
b Values are expressed as nanograms of peptide per g of brain (wet weight) derived from duplicate or triplicate determinations of each animal.
FIG. 2. Cumulative survival curves (Kaplan-Meier survival
analysis) of TgCRND8 mice in different genetic backgrounds.
Cumulative survival curves of TgCRND8 mice as a function of the
transgene genetic background. The survival of Tg mice on the (C57) 3
(C3H/C57) genetic background (n 5 52) was the highest, with 50% of
mice surviving until 365 days of age (upper cut-off of the analysis). In
contrast, the survival of the Tg mice on (C3H/C57/129SvEv/Tac) 3
(129SvEv/Tac) and (FVB)3(C3H/C57) backgrounds (n 5 12 and n 5 41
respectively) was affected by increased mortality within the first 120
days of their post-natal age. In the case of Tg mice with the (C3H/C57/
129SvEv/Tac) 3 (129SvEv/Tac) genetic background, only 3 (25%) out of
12 mice survived until the age of 365 days, and only 17% (7 out of 41) of
the (FVB) 3 (C3H/C57) Tg mice reached the age of 365 days.
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NSP for the groups were not significantly different (50.0 6 7.3
versus 57.6 6 8.8 s for latency and 961.1 6 165.0 versus 1351 6
247.4 cm for path-length, for the non-Tg and Tg mice, respec-
tively). A “visible platform trial” administered during NSP,
where the position of the submerged platform was marked by a
striped beacon, also failed to reveal differences in performance
between non-Tg and Tg groups. Average latencies to reach the
cued platform were 9.9 6 2.0 and 9.1 6 1.6 s for non-Tg and Tg
mice, respectively. The swim paths were 167.3 6 16.1 cm for
non-Tg and 153.1 6 14.2 cm for Tg mice, and both groups had
comparable swim speeds of 21.6 6 1.4 and 20.2 6 1.7 cm/s for
non-Tg and Tg mice, respectively. In conclusion, these analyses
showed TgCRND8 mice performed a random search compara-
ble to non-Tg littermates when presented with the submerged
platform and had similar swim paths to a visible platform
when extra-maze distal spatial cues were occluded by a curtain.
Water Maze, Reference Memory Test—TgCRND8 mice at 11
weeks showed impairment in the acquisition of spatial infor-
mation during place discrimination training. They had signif-
icantly longer escape latencies to reach the escape platform
(Fig. 3A; F(1,15) 5 17.98, p , 0.001) and longer search paths
(F(1,15) 5 15.91, p , 0.001). Both, Tg and non-Tg groups
significantly improved during training (F(4,60) 5 3.29, p ,
0.02; F(4,60) 5 3.33, p , 0.02, the latency and path, respec-
tively), and no significant interaction between the groups and
sessions was found in both measures. The concordance between
measures of latency and search path is not surprising, because
the TgCRND8 mice did not differ significantly from the non-Tg
littermates in their swim speed during the test (F(1,15) 5 2.53,
p . 0.05). The pronounced spatial learning impairment of Tg
mice was confirmed during the probe trial administered after
the completion of training. They showed lower (t(15) 5 2.99,
p 5 0.01) annulus crossing index (Fig. 3B), searching the pool
in a circular fashion and frequently crossing the centers of
alternative quadrants (with an annulus crossing index ap-
proaching a zero value).
Neuropathology in TgCRND8 Mice
TgCRND6 mice expressing the Swedish mutant form of APP
(see Fig. 1) on a B6 3 C3H background failed to exhibit cerebral
amyloid at ages up to 450 days. Similar results were obtained
for two other Tg lines resulting from the microinjection of the
same DNA construct into a FVB/N 3 129SvEv/Tac background
(not shown). On the other hand, hemizygous TgCRND8 mice
expressing the double mutant form of APP exhibited potent
deposition of cerebral amyloid, present in all animals by 90
days of age. In contrast to PDAPP mice expressing a V717F
APP transgene (21), no difference in the volume of the dorsal
hippocampus (or in the surrounding regions) was detected be-
tween Tg and non-Tg mice (p , 0.05 for all values). In
TgCRND8 mice, the dorsal hippocampus occupied ;11.0 6
0.3% of the volume of coronal sections (means 6 S.E. of the
mean), whereas in the non-Tg mice this value was 10.3 6 0.2%.
Also, the neuronal cytoarchitecture of the TgCRND8 mice ap-
peared normal.
Amyloid deposits in TgCRND8 mice were successfully
stained with Ab42-specific antibodies, as anticipated from prior
studies of the mechanism of action of the V717F mutation (5).
In addition to confirming dense-cored deposits in aged
TgCRND8 mice, the human APP-specific monoclonal antibody
4G8, and to a lesser extent monoclonal antibody 6F/3D, also
detected diffuse immuno-staining in the neuropil (using formic
acid-treated sections: Fig. 4B). These findings were compatible
with both the previously described specificity of the 4G8 anti-
body (42, 43), and the propensity of other mice expressing APP
codon 717 mutations to generate “diffuse” amyloid deposits (19,
21, 23). Although human APP was also expressed systemically
in TgCRND8 mice, in accord with the tropism of the PrP gene
promoter (44), amyloid deposits were not apparent by immu-
nostaining in the kidney, lung, skeletal, and cardiac muscle of
aged animals (not shown). These observations suggest a role for
tissue-specific factors affecting amyloid deposition and/or APP
processing.
Plaque Ontogeny—A single plaque was noted in one
TgCRND8 animal at 43 days. Plaque load increased with age
and spread to more regions of the brain such that multiple
plaque deposits were present per sagittal section in most mice
at 65 days of age, and in all mice by 90 days of age. Although
studies on large cohorts of mice are in progress, analyses of
representative mice revealed between 11–35 and 22–43
plaques in a mid-sagittal section of the cortex at the ages of 90
and 150 days, whereas burdens were greatly increased at 240
and 350 days of age (127–416 and 528–1024 plaques, respec-
tively). A similar pattern of increase pertained to the hip-
pocampal formation with 1–5 and 11–12 plaques at 90 and 150
days and 39–65 and 123–147 plaques at 240 and 360 days,
respectively. Thus, the time period for a rapid increase in
amyloid burden assessed histologically lags slightly behind
that determined biochemically by ELISA assays (Table I).
Plaque Distribution—The plaque present at 43 days was
located in the subiculum. The frontal cortex of TgCRND8 mice
often had several plaques by 65 days, whereas plaques were
rare or absent in the white matter tracts (corpus callosum and
alveus) and CA1 region of the hippocampus at this time. By 101
days plaques were widespread in many regions of the cortex as
well as in the hippocampus proper, the dentate gyrus, the
FIG. 3. Reference memory version of Morris water maze test in
TgCRND8 mice. A, at 11 weeks of age, experimentally naive
TgCRND8 mice (NTg 5 10) show significant impairment in the acqui-
sition of the spatial information relative to their non-Tg littermates
(Nnon-Tg 5 7). B, represents an annulus crossing index (the number of
passes over the platform site in TQ, minus the mean of passes over
alternative sites in other quadrants) during the probe trial adminis-
tered after the last training trial of day 5. A positive index indicates
selective focal search of the previous platform position, an index ap-
proximating zero reflects non-spatial or circular search of the pool. The
TgCRND8 mice showed a significantly impaired (p , 0.01) spatial bias
for the platform position as compared with their non-Tg littermates. *,
p , 0.01. Vertical bars represent S.E.
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olfactory bulb, and within the pial vessels. The thalamus (111
days), then the cerebral vasculature and striatum (196 days),
followed by the cerebellum and brain stem (243 days) all be-
came progressively burdened by plaques. This pattern of dep-
osition, with cortex and hippocampus affected early on and the
cerebellum spared until a late stage in disease, is similar to
that seen in AD (45).
Plaque Morphology—The first plaques observed were small,
cored deposits, with no radiating amyloid surrounding them
(65 days). By 101 days, the plaques varied in size, with some
larger plaques having haloes of radiating amyloid. By 131 days
the plaques became more heterogeneous in nature. Plaques
varied greatly in size as the age of the mice increased, with
some being multicored in older animals. Diffuse amyloid de-
posits appeared in the olfactory bulb at an early stage (101
days). However, outside of the olfactory bulb, diffuse amyloid
(i.e. amyloid not obviously associated with a cored plaque) did
not appear until 243 days, as detected with the 6F/3D antibody.
Diffuse amyloid was found primarily in the caudate, cerebel-
lum, and molecular layer of the dentate gyrus (all at 243 days).
By 315 days diffuse amyloid appeared throughout the cortex
(see Fig. 4B).
The majority of amyloid plaque deposits in TgCRND8 mice,
including those first to appear at 65 days, stained positive for
thioflavine S. These early deposits also revealed Congo Red
birefringence. Together these data indicate the deposited amy-
loid peptide adopts a b-sheet conformation. Amyloid plaques in
TgCRND8 mice were associated with dystrophic neurites, as
indicated by a variety of histochemical and immunohistochem-
ical stains (Fig. 4). For example, Bielschowsky silver impreg-
nation revealed dystrophic neuritic processes around plaque
cores (Fig. 4E). Similar structures were imaged by antibodies
raised against the 200-kDa isoform of neurofilament (NF-200;
Fig. 4F), synaptophysin (Fig. 4G), and ubiquitin (Fig. 4H). The
first enlarged plaque-associated neurites were seen with
Bielschowsky, synaptophysin, and NF-200 staining at 111 days
of age. Dystrophic pathology became more evident as the mice
aged further and the frequency of large, dense-cored plaques
increased. Finally, it was noteworthy that dystrophic neurites
were only observed in the immediate vicinity of plaques, indi-
cating these structures are a direct consequence of amyloid
deposition in the TgCRND8 mice.
Neuroinflammation—Mature plaques in TgCRND8 mice
were associated with a focal inflammatory response. Elongated
cells in periphery of dense-cored amyloid deposits visualized by
Luxol fast blue staining or focal staining with a Griffonia
simplicifolia lectin I isolectin B4 stain (not presented) and
staining with anti-CD11b antibody probe (Fig. 4I) were consist-
ent with the presence of microglial cells. This microglial acti-
vation was accompanied by intense local astrocytic gliosis, il-
lustrated by GFAP staining of adjacent sections encompassing
a thioflavin-positive plaque (Fig. 4, K and J). This astrocytic
response clearly exceeded a low basal level of staining of GFAP-
positive astrocytes (mostly evident within white matter tracts)
noted in both transgenic and non-transgenic mice.
Acceleration of Amyloid Deposition by Co-expression of
Presenilin-1 Transgenes
Amyloid deposition in TgCRND8 mice was enhanced by mu-
tant human PS1 transgenes co-expressed with human APP via
usage of the same cos.Tet transgene vector (Fig. 5, right-hand
panels). This effect was evident in terms of a potent increment
in plaque burden over age-matched TgCRND8 single trans-
genic controls. Conversely, expression of wt human PS1 had no
overt effect upon amyloid burden (not shown). With a PS1
transgene incorporating two FAD mutations in cis (M146L and
L286V (46)), the potentiation was particularly remarkable.
Here there was robust deposition of plaques by 30–45 days of
age (33 days of age presented in Fig. 5B). Notably, the graded
effects observed for wild type, single, and double mutant trans-
genes upon amyloid deposition cannot be attributed to different
PS1 expression levels, as these were very closely matched
between the three selected TgPS1 lines (wild type, mutant, and
double mutant, Fig. 1C).
DISCUSSION
Factors Affecting APP Transgenesis—Although transgenesis
is generally regarded as a routine technique, the APP gene,
FIG. 4. Properties of amyloid depos-
its from TgCRND8 mice. A, sagittal
section of an 8-month-old TgCRND8
mouse immunostained with 4G8 anti-Ab
antibody: Cer, cerebellum; HPC, hip-
pocampus; N, neocortex; OB, olfactory
bulb. B, dentate gyrus (3 400 magnifica-
tion) in a 12-month-old TgCRND8 mouse
immunostained with 6F/3D antibody and
illustrating different varieties of amyloid
deposits: dense-cored (red arrow), multi-
cored (gray arrow), and diffuse (black ar-
row). C–K illustrate the tinctorial and im-
munostaining profiles of amyloid deposits
in a 5.5-month-old TgCRND8 mice (3 400
magnification). C, staining with Congo
Red showed typical apple green and or-
ange birefringence with a polarized light
source. D, perivascular amyloid stained
with thioflavine S (white arrows).
Bielschowsky stain (E) and NF-200 (F)
reveal dystrophic neurites (arrows) adja-
cent to plaques (P). G and H represent
synaptophysin and ubiquitin-positive
structures in the periphery of plaque de-
posits, indicative of dystrophic buttons.
I–K illustrate focal inflammatory re-
sponses. I, anti-CD11b antibody, J, thio-
flavine S stain of an adjacent section, and
K, GFAP staining of a third adjacent
section.
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first cloned over a decade ago, can be seen to present particular
challenges. Difficulties encountered thus far include low ex-
pression levels in first generation Tg mice, neonatal lethality
associated with high level expression in second generation
mice, and physiological endoproteolysis to generate multiple
subfragments with diverse biological activities, some of which
(e.g. neuroprotection (reviewed in Ref. 47) may confound the
study of neuropathogenesis. We modified a number of param-
eters in our experimental design in an effort to reduce the
“noise” from these confounding effects and thereby facilitate
study of the pathogenic attributes of the Ab peptide; such
pathogenic attributes are clearly suggested by genetic, neuro-
pathological, and toxicological studies (12–14, 48). Our strategy
involved using the following: (i) an expression cassette that
retained ;90 nucleotides of the APP mRNA 59-untranslated
region adjacent to the start codon, as APP is expressed at high
levels for a single copy gene and likely already contains opti-
mized translational initiation signals; (ii) a prion protein cos-
mid vector that can drive high level pan-neuronal expression in
the central nervous system; (iii) two pro-endoproteolytic FAD
mutations, to obtain a high level of Ab peptide for a given level
of APP expression; and (iv) use of a genetic background that
may offer a degree of protection against high level APP expres-
sion favored by parameters i and ii.
It is possible that genetic background may have been impor-
tant for establishing the TgCRND8 line. Our strategy was
based upon the hypothesis that dominant alleles protective
against APP overexpression present in the C3H background
(36) would facilitate the establishment of Tg lines with high
levels of expression. As injections into C3H oocytes are not
usually attempted, the TgCRND8 line was established in an
outbred C3H/B6 background. Survival curves presented here
document that in TgCRND8 mice high levels of Ab peptide and
modest levels of APP a- and b-stubs can be tolerated in a
C3H/B6 genetic background without grossly compromising vi-
ability (Fig. 2). Whereas these data are in accord with the
starting hypothesis, they are incompatible with facile genetic
analysis, as confounding effects due to independent segregation
of alleles from the C3H and B6 strains conferring protection or
sensitivity to APP overexpression cannot be excluded. Experi-
ments to establish C3H congenic lines of TgCRND8 mice will
lead to more definitive information on this point. Furthermore,
it is of interest to note that the KM670/NL6711V717F con-
struct injected into oocytes from another potentially protective
genetic background (129SvEvTac 3 FVB/N (36)) yielded a
transgenic line designated Tg19959, which also exhibits cere-
bral plaques at 3 months of age (data not shown). In sum, our
results suggest manipulation of genetic background may re-
duce postnatal death associated with APP overexpression and
should be considered in strategies for APP transgenesis. How-
ever, insofar as parameters i–iv have been used individually in
the creation of APP Tg mice (8, 17–19, 22, 23), it is plausible
that a synergism between all four parameters contributes to
the desirable properties of TgCRND8 mice.
Biochemistry of TgCRND8 Mice—With the possible excep-
tion of the Tg19959 line, TgCRND8 mice are currently unique
FIG. 5. Ab-containing plaques in the cortex of single and dou-
ble transgenic mice. Panels show sagittal sections of the neocortex
adjacent to the hippocampus. Left-hand panels (A and C) depict “single”
transgenic TgCRND8 mice. Right-hand panels (B and D) depict “dou-
ble” transgenic TgCRND8 mice co-expressing either human presenilin
1 (B, TgPS1(M146L1L286V)6500; D, TgPS1(L286V)1274). Each hori-
zontal row represents single and double -Tg littermates at the same age:
A and B, 33 days; C and D, 62 days. Immunohistochemical analyses
presented were obtained with the 4G8 monoclonal antibody. Note en-
hanced plaque deposition in double Tg animals. 3 400 magnification.
TABLE II
Amyloid deposition in APP transgenic mice
Tg line Ab42 pmol/ga Ab40 Ab42/40 Plaqueonset Ref.
age monthsb pmol/gc months
PDAPP 615 6 333 (12) ;79c ;7.8 6–9 17
Tg2576 175 6 26 (11–13) 264 6 38 0.7 9 18
TgAPP/V717Id ;170 (15) ;440 ;0.4 13 73
TgCRND8 4,600 6 1,560 (6) 2,440 6 350 2.0 3 This paper, (1)
3200 6 350e (6) 920 6 125 3.5
a Results of Ab ELISAs are expressed per g (wet weight of brain). Transgenic mice are listed chronologically. Some values derive from formic acid
extraction, whereas others use a guanidinium-hydrochloride procedure. Some values were converted from ng to g using values of 4328 and 4513
Da for Ab 40 and 42, respectively.
b Except for the TgAPP/V717I line, all Ab values are reported for a time point 3 months after the first onset of plaque deposition, as determined
histologically. These time points are given in months (in parentheses).
c Ab40 was calculated by subtraction of Ab42 from total Ab values.
d ELISA values represent plaque-associated (insoluble) Ab.
e Second set of ELISA values derive from a control group of TgCRND8 mice immunized with islet-associated polypeptide (1).
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among single transgenic APP mice with regard to the severity
of Ab deposition. Histological deposition of Ab in amyloid
plaques in TgCRND8 mice is evident in 100% of animals by 3
months after birth (n 5 28), earlier than in APP transgenic
lines described previously (17–19, 49). These results find a
parallel in measurements of Ab40 and Ab42 derived from
ELISA assays (Tables I and II); for example, levels of Ab42 in
6-month-old TgCRND8 mice approximate those seen in PDAPP
mice at 16 months of age (31). Furthermore, two results emerg-
ing from these ELISAs show a direct parallel to AD pathogen-
esis and bear particular emphasis. First, the levels of total Ab
in TgCRND8 mice at 6 months of age, 3,200–4,600 pmol/g
brain (as determined by two independent ELISA configura-
tions employing different antibodies), fall into the range ob-
served for sporadic AD cases, 500–5000 pmol/g wet tissue (50).
Second, the ratio of Ab42 to Ab40 exceeds unity, as is also the
case in sporadic AD (50) (and in PDAPP mice expressing a
V717F mutation (31)). Insofar as Ab42 is thought to be the
most aggregation-prone and toxic form of Ab, the skew toward
the production of Ab42 apparent in these mice presumably
contributes to the unusually early onset of amyloid deposition.
Although the combined effect of the two FAD mutations
affecting both b- and g-secretase processing of APP is pre-
sumed to be a powerful determinant of this potent amyloido-
genesis, it is notable that other “double mutant” TgAPP mice
only show 100% of animals positive for plaques at 8–10, 18, or
21–25 months of age (19, 49, 51). Although the degree of APP
overexpression could also prove crucial in distinguishing
TgCRND8 mice from other double mutant TgAPP lines, further
variables include PrP, thy-1, or platelet-derived growth fac-
tor-b promoters with different tropisms and different APP cod-
ing region cassettes (APP695, APP751, or intron-containing
cassettes capable of producing all three APP isoforms).
Finally, it is remarkable that even though TgCRND8 mice
exhibit a high basal synthesis of Ab, levels of this peptide can
be elevated to yet higher levels by mutant versions of PS1.
Importantly, two PS1 mutations in cis shown to act in an
additive way in transfected cells (46) behave in a similar fash-
ion in vivo. Thus, double transgenic mice incorporating 4 FAD
mutations can develop Ab deposits by 1 month of age (Fig. 5B).
Neuropathology in Transgenic Models of Alzheimer’s Dis-
ease—TgCRND8 mice exhibit AD-like amyloid plaque deposits
with a variety of morphologies. Dense-cored deposits are pres-
ent from an early stage, and the majority of these (.80%) can
be stained with either Congo Red or thioflavine S. With aging,
the plaques become larger and multicentric dense-cored depos-
its appear. Diffuse Ab immunostaining is also apparent at later
stages, being particularly prominent after formic acid pretreat-
ment. Diffuse staining is evident as a penumbra around large
plaques and also in the form of isolated deposits (i.e. not obvi-
ously associated with plaques) throughout the neuropil. From 5
months of age the mature plaques in TgCRND8 mice exhibit
neuritic changes strikingly similar to those seen in AD (Fig. 4).
Dystrophic neurites are revealed by silver impregnation or
NF-200 immunostaining, with dystrophic boutons visualized
by synaptophysin or ubiquitin antibodies. Astrocytes and mi-
croglial cells often encircle dense-cored deposits, indicating the
plaques are capable of initiating an inflammatory response.
The other pathological hallmarks of AD are generally accepted
to include neuronal loss and the accumulation of NFTs. Focal
neuronal loss has been reported in only one Tg model of AD (20,
52, 53), and analogous studies in TgCRND8 mice are under-
way. NFTs are absent in TgCRND8 mice, as indeed they are in
other TgAPP mice. It is possible coding sequence divergence
between mouse and human may be of importance, and expres-
sion of human tau and cognate tau kinases, perhaps the p25
fragment of p35 (54, 55) or glycogen synthese kinase 3b, may be
required to fully recapitulate this pathology.
The Origins of Cognitive Dysfunction in Alzheimer’s Dis-
ease—In Alzheimer’s disease patients, pathological changes
detected post-mortem are foreshadowed in the clinical presen-
tation by erosion of mental function leading to frank dementia.
Therefore, plausible animal models of AD should develop cog-
nitive deficits at least by the time of appearance of AD-related
neuropathology. TgCRND8 mice fulfill this expectation. They
represent an example of mice expressing full-length APP where
deficits in acquisition of spatial reference memory are present
at the onset of AD-related neuropathology (Fig. 3) (1) and thus
exhibit some similarities to Tg2576 mice (18, 24). In studies of
other TgAPP mice, impaired performance in the water maze
test preceded neuropathological changes (23) or was not re-
ported (19). Impaired performance in other testing paradigms
has been reported in PDAPP V717F mice, but here a subset of
cognitive deficits was better correlated to confounding neuro-
anatomical abnormalities than to AD-related pathologies (21,
25). In the most recent studies, an age-related deficit in learn-
ing capacity was detected in PDAPP mice using a new water
maze testing regimen (56). Nonetheless, from a practical point
of view, the cognitive deficits in TgCRND8 mice have three
important attributes as follows: they occur early in life; they
are easily detected in the conventional spatial reference mem-
ory version of the water maze; and they are sufficiently robust
to be detected without recourse to large sample sizes.
Although overaccumulation of the Ab peptide is firmly im-
plicated in AD pathogenesis, the mechanisms leading to cogni-
tive decline are not clear. As attempts to correlate plaque
burdens and cognitive deterioration have produced mixed re-
sults (see Refs. 57–65 and also see Ref. 56), it is possible Ab
affects the central nervous system by mechanisms other than
(or in addition to) the toxicity of extracellular, aggregated
forms. Indeed, recent studies emphasize soluble forms of Ab as
crucial determinants of clinical outcome (50, 66, 67). Unfortu-
nately, the molecular determinants for neurotoxicity (for exam-
ple, free radical generating capacity of metal-bound Ab42 (68,
69) and perturbed signal transduction (70)) and the cellular
consequences thereof (altered synaptic function, excitotoxicity,
and induction of apoptosis (49, 66)) are undetermined. We
suggest TgCRND8 mice comprise a useful and validated sys-
tem to address these issues. Amelioration of cognitive deficits
by immunization against Ab42 peptide (1) provides compelling
evidence for a strong pathogenic role for Ab peptide in the
TgCRND8 model of AD and indeed for the amyloid cascade
hypothesis. Parenthetically, these data effectively exclude the
proposition that cognitive deficits in TgCRND8 mice derive
from an insertional mutation. Furthermore, synthesis of anti-
sera in Ab42-immunized mice that react strongly with the
peptide presented in a b-sheet conformation (1) suggests a
potential to dissect the mechanism of Ab neuropathogenesis
(for example, by passive immunization (71) with conformation-
specific antibodies). In short, the availability of a new AD
model with robust cognitive deficits, levels of Ab peptide that
equal those seen in AD cases, and AD-like pathology may allow
both an improved understanding of causal relationships be-
tween these phenotypic traits and testing of candidate
interventions.
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